Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 7 (July)

1. Autonomous Hedgehog signalling is undetectable in PC-3 prostate cancer cells.
   Biochem Biophys Res Commun, 373(1): 109-12. [Abstract] [Full-text]
2. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
   Clin Cancer Res, 14(13): 4241-9. [Abstract] [Full-text]
3. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
   Clin Cancer Res, 14(13): 4200-5. [Abstract] [Full-text]
4. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.
   Clin Cancer Res, 14(13): 4111-8. [Abstract] [Full-text]
5. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.
   Cancer Res, 68(13): 5469-77. [Abstract] [Full-text]
6. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression.
   Cancer Res, 68(13): 5460-8. [Abstract] [Full-text]
7. Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics.
   Br J Cancer, 99(1): 78-82. [Abstract] [Full-text]
8. Multiple loci with different cancer specificities within the 8q24 gene desert.
   J Natl Cancer Inst, 100(13): 962-6. [Abstract] [Full-text]
9. Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study.
   Br J Cancer, 99(1): 176-8. [Abstract] [Full-text]
10. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
    Am J Surg Pathol, 32(7): 1060-7. [Abstract] [Full-text]
11. Management of acquired rectourinary fistulas: how often and when is permanent fecal or urinary diversion necessary?
    Dis Colon Rectum, 51(7): 1049-54. [Abstract] [Full-text]
12. Cyclic adenosine monophosphate differentiated beta-endorphin neurons promote immune function and prevent prostate cancer growth.
    Proc Natl Acad Sci U S A, 105(26): 9105-10. [Abstract] [Full-text]
13. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
    Urology, 72(1): 95-8. [Abstract] [Full-text]
14. Robotic prostatectomy: a review of outcomes compared with laparoscopic and open approaches.
    Urology, 72(1): 15-23. [Abstract] [Full-text]
15. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
    Urology, 72(1): 143-7. [Abstract] [Full-text]
16. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
    Urology, 72(1): 167-71. [Abstract] [Full-text]
17. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.
    Urology, 72(1): 172-6. [Abstract] [Full-text]
18. Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case-control study.
    Urology, 72(1): 183-7. [Abstract] [Full-text]
19. Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years.
    Urology, 72(1): 177-82. [Abstract] [Full-text]
20. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
    J Med Chem, 51(13): 3895-904. [Abstract] [Full-text]
21. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
    JAMA, 300(2): 173-81. [Abstract] [Full-text]
22. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
    BJU Int, 102(2): 253-8. [Abstract] [Full-text]
23. Familial myeloma.
    N Engl J Med, 359(2): 152-7. [Abstract] [Full-text]
24. Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer.
    Ann Diagn Pathol, 12(4): 260-6. [Abstract] [Full-text]
25. Salvage prostate cryoablation: initial results from the cryo on-line data registry.
    J Urol, 180(2): 559-63; discussion 563-4. [Abstract] [Full-text]
26. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
    J Urol, 180(2): 565-70; discussion 570. [Abstract] [Full-text]
27. Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
    J Urol, 180(2): 571-6; discussion 576. [Abstract] [Full-text]
28. Health risk behaviors and prostate specific antigen awareness among men in California.
    J Urol, 180(2): 658-62; discussion 662. [Abstract] [Full-text]
29. Total prostate specific antigen stability confirmed after long-term storage of serum at -80C.
    J Urol, 180(2): 534-7; discussion 537-8. [Abstract] [Full-text]
30. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.
    J Urol, 180(2): 539-43; discussion 543. [Abstract] [Full-text]
31. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
    J Urol, 180(2): 554-8. [Abstract] [Full-text]
32. The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.
    J Urol, 180(2): 548-52; discussion 552-3. [Abstract] [Full-text]
33. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
    J Urol, 180(2): 451-9; discussion 460. [Abstract] [Full-text]
34. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
    J Urol, 180(2): 544-7. [Abstract] [Full-text]
35. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer.
    Br J Cancer, 99(2): 314-20. [Abstract] [Full-text]
36. Rapid progression of prostate cancer in men with a BRCA2 mutation.
    Br J Cancer, 99(2): 371-4. [Abstract] [Full-text]
37. Secular trends in mortality from common cancers in the United States by educational attainment, 1993-2001.
    J Natl Cancer Inst, 100(14): 1003-12. [Abstract] [Full-text]
38. Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.
    J Natl Cancer Inst, 100(14): 1022-36. [Abstract] [Full-text]
39. Effects of DNAzymes targeting Aurora kinase A on the growth of human prostate cancer.
    Cancer Gene Ther, 15(8): 517-25. [Abstract] [Full-text]
40. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.
    Oncogene, 27(31): 4353-62. [Abstract] [Full-text]
41. Extracellular redox state regulates features associated with prostate cancer cell invasion.
    Cancer Res, 68(14): 5820-6. [Abstract] [Full-text]
42. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.
    Cancer Res, 68(14): 5785-94. [Abstract] [Full-text]
43. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.
    Cancer Res, 68(14): 5599-608. [Abstract] [Full-text]
44. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.
    Prostate, 68(12): 1319-29. [Abstract] [Full-text]
45. Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus.
    Prostate, 68(12): 1354-61. [Abstract] [Full-text]
46. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.
    Prostate, 68(12): 1283-95. [Abstract] [Full-text]
47. Translationally regulated C/EBP beta isoform expression upregulates metastatic genes in hormone-independent prostate cancer cells.
    Prostate, 68(12): 1362-71. [Abstract] [Full-text]
48. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.
    Prostate, 68(12): 1341-53. [Abstract] [Full-text]
49. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
    Prostate, 68(12): 1307-18. [Abstract] [Full-text]
50. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort.
    Prostate, 68(12): 1336-40. [Abstract] [Full-text]
51. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations.
    Prostate, 68(12): 1257-62. [Abstract] [Full-text]
52. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.
    BMC Med, 6: 19. [Abstract] [Full-text]
53. Statin use and risk of prostate cancer: results from a population-based epidemiologic study.
    Am J Epidemiol, 168(3): 250-60. [Abstract] [Full-text]
54. Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis.
    Radiology, 248(2): 531-9. [Abstract] [Full-text]
55. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 71(5): 1496-503. [Abstract] [Full-text]
56. Comparison of combined x-ray radiography and magnetic resonance (XMR) imaging-versus computed tomography-based dosimetry for the evaluation of permanent prostate brachytherapy implants.
    Int J Radiat Oncol Biol Phys, 71(5): 1518-25. [Abstract] [Full-text]
57. Image guidance based on prostate position for prostate cancer proton therapy.
    Int J Radiat Oncol Biol Phys, 71(5): 1322-8. [Abstract] [Full-text]
58. In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval.
    Int J Radiat Oncol Biol Phys, 71(5): 1295-301. [Abstract] [Full-text]
59. Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10.
    Int J Radiat Oncol Biol Phys, 71(5): 1309-15. [Abstract] [Full-text]
60. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 71(5): 1302-8. [Abstract] [Full-text]
61. Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease?
    Int J Radiat Oncol Biol Phys, 71(5): 1316-21. [Abstract] [Full-text]
62. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.
    Biochem Biophys Res Commun, 373(3): 423-8. [Abstract] [Full-text]
63. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis.
    Anesthesiology, 109(2): 180-7. [Abstract] [Full-text]
64. Androgen deprivation by activating the liver X receptor.
    Endocrinology, 149(8): 3778-88. [Abstract] [Full-text]
65. Expression and function of fatty acid amide hydrolase in prostate cancer.
    Int J Cancer, 123(6): 1318-26. [Abstract] [Full-text]
66. Joint effects of inflammation and androgen metabolism on prostate cancer severity.
    Int J Cancer, 123(6): 1385-9. [Abstract] [Full-text]
67. Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells.
    Int J Cancer, 123(6): 1255-61. [Abstract] [Full-text]
68. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
    Oncogene, 27(32): 4422-33. [Abstract] [Full-text]
69. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials.
    Cancer Metastasis Rev, 27(3): 375-85. [Abstract] [Full-text]
70. Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer.
    BMC Health Serv Res, 8: 146. [Abstract] [Full-text]
71. Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells.
    Biochem Biophys Res Commun, 373(4): 618-23. [Abstract] [Full-text]
72. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
    Hum Mol Genet, 17(16): 2456-61. [Abstract] [Full-text]
73. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.
    Cancer Immunol Immunother, 57(10): 1451-9. [Abstract] [Full-text]
74. Association of HSP70-hom genetic variant with prostate cancer risk.
    Mol Biol Rep, 35(3): 459-64. [Abstract] [Full-text]
75. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development.
    J Clin Pathol, 61(8): 891-6. [Abstract] [Full-text]
76. Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells.
    J Cell Physiol, 217(1): 184-93. [Abstract] [Full-text]
77. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer.
    Br J Cancer, 99(3): 491-501. [Abstract] [Full-text]
78. Positive surgical margins in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy: histologic features and pitfalls.
    Am J Surg Pathol, 32(8): 1201-6. [Abstract] [Full-text]
79. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
    Oncogene, 27(33): 4569-79. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.